A single-arm, observational, single-center, open label study for Toripalimab with or without Paclitaxel (albumin bound) plus Tegafur, Gimeracil and Oteracil Potassium Capsules as a Neoadjuvant therapy for esophageal cancer before operation
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Toripalimab (Primary) ; Gimeracil/oteracil/tegafur; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Therapeutic Use
- 01 Sep 2024 Results of an analysis assessing efficacy and safety of neoadjuvant chemo-immunotherapy in patients with ESCC, focusing on surgical outcomes and molecular profile from a cohort of 67 patients from this trial published in the Oncogene
- 21 Sep 2020 Interim results (n=24; data cut off date- April 24, 2020) presented at the 45th European Society for Medical Oncology Congress
- 04 Feb 2020 New trial record